Pharmacoeconomic analysis of ferric carboxymaltose in patients with chronic heart failure and iron deficiency in the Russian Federation

Abstract

Aim: To evaluate the economic efficiency of using ferric carboxymaltose (FCM) in patients with chronic heart failure with reduced left ventricular ejection fraction (CHFrEF) and iron deficiency (ID) in the Russian Federation Methods: The analysis of the cost of maintaining CHFrEF with ID was carried out and an analytical decision-making model was built in MS Excel, which allows estimating the costs from the position of the state in the management of patients with CHFrEF with ID when using FCM in comparison with placebo. Results: The use of FCM in 633,301 patients with CHFrEF and ID for 1 year will prevent 72,386 hospitalizations for CHF and reduce the number of days spent by patients in the hospital by 1,136,141 days. Taking into account the direct costs of stopping adverse events, as well as the indirect costs of paying disability benefits and GDP losses, the potential economic benefit of using FCV when prescribing 633,301 CHFrEF and DJ to patients for 1 year can be 4.280 million rubles. per year of therapy. The use of FCM in patients with CHFrEF and ID is advisable immediately after an episode of CHF decompensation in order to reduce the risk of subsequent hospitalizations for worsening CHF and increase the cost per patient by only 4 642 rubles. per year (18 %), while significantly improving the prognosis of patients and their quality of life. Conclusion: FCM can be recommended for inclusion in the standards of medical care, clinical guidelines, formularies of healthcare facilities, application templates within the framework of the regional (RLO) and federal drug benefits, as well as federal and regional programs aimed at improving the control of the clinical course CHFrEF with ID.